Insulin-sensitizing agents and reproductive function in polycystic ovary syndrome patients

Current Opinion in Obstetrics and Gynecology

Volumn 20, Issue 4, 2008, Pages 364-373

  Palomba, Stefano ^a   Falbo, Angela ^a   Orio, Francesco ^b   Zullo, Fulvio ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b UNIVERSITY OF NAPLES PARTHENOPE   (Italy)

Author keywords

Infertility; Insulin sensitizers; Metformin; Ovulation induction; Polycystic ovary syndrome; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CLOMIFENE CITRATE; INSULIN; INSULIN SENSITIZING AGENT; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; TROGLITAZONE; ANTIDIABETIC AGENT;

BIRTH; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFECT; DRUG EFFICACY; FEMALE INFERTILITY; HORMONAL REGULATION; HUMAN; HYPERANDROGENISM; MENSTRUAL CYCLE; MENSTRUATION; METABOLIC BALANCE; MONOTHERAPY; OPEN STUDY; OUTCOME ASSESSMENT; OVARY INSUFFICIENCY; OVARY POLYCYSTIC DISEASE; OVULATION; PREECLAMPSIA; PREGNANCY; PREGNANCY DIABETES MELLITUS; PREGNANCY TERMINATION; PRIORITY JOURNAL; REPRODUCTION; REVIEW; SPONTANEOUS ABORTION; SYSTOLIC BLOOD PRESSURE; TERATOGENICITY; ARTICLE; CHEMICALLY INDUCED DISORDER; FEMALE; OVULATION INDUCTION; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; RANDOMIZED CONTROLLED TRIAL;

FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; OVULATION INDUCTION; POLYCYSTIC OVARY SYNDROME; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 58149269401     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/GCO.0b013e328307ebc5     Document Type: Review

References (103)

1. Asunción M, Calvo RM, San Millán JL, et al. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000; 85:2434-2438.
2. Azziz R, Woods KS, Reyna R, et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004; 89:2745-2749.
3. Azziz R, Marin C, Hoq L, et al. Healthcare-related economic burden of the polycystic ovary syndrome during the reproductive life span. J Clin Endocrinol Metab 2005; 90:4650-4658.
4. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81:19-25.
5. Boomsma CM, Eijkemans MJ, Hughes EG, et al. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum Reprod Update 2006; 12:673-683.
6. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997; 18:774-800.
7. Saenz A, Fernandez-Esteban I, Mataix A, et al. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005; (20):CD002966.
8. Velazquez EM, Mendoza S, Hamer T, et al. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandro-genemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 1994; 43:647-654.
9. DeFronzo RA. Pathogenesis of type 2 diabetes: implications for metformin. Drugs 1999; 58 (Suppl 1):29-30.
10. Stumvoll M, Nurjhan N, Perriello G, et al. Metabolic effects of metformin in noninsulin-dependent diabetes mellitus. N Engl J Med 1995; 333:550- 554.
11. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996; 334:574-579.
12. Palomba S, Russo T, Orio F Jr, et al. Uterine effects of metformin administration in anovulatory women with polycystic ovary syndrome. Hum Reprod 2006; 21:457-465.
13. Palomba S, Orio F Jr, Falbo A, et al. Effects of metformin and clomiphene citrate on ovarian vascularity in patients with polycystic ovary syndrome. Fertil Steril 2006; 86:1694-1701.
14. Lord JM, Flight IH, Norman RJ. Insulin-sensitising drugs (metformin, troglita-zone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst Rev 2003; (3):CD003053.
15. Ratner RE, The Diabetes Prevention Program Research. An update on the Diabetes Prevention Program. Endocr Pract 2006; 1:20-24.
16. Dunaif A, Scott D, Finegood D, et al. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996; 81:3299-3306.
17. Diamanti-Kandarakis E, Kouli C, Tsianateli T, et al. Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Eur J Endocrinol 1998; 138:269-274.
18. Morin-Papunen LC, Koivunen RM, Ruokonen A, et al. Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. Fertil Steril 1998; 69:691-696.
19. Glueck CJ, Wang P, Fontaine R, et al. Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome. Metabolism 1999; 48:511-519.
20. Unluhizarci K, Kelestimur F, Bayram F, et al. The effects of metformin on insulin resistance and ovarian steroidogenesis in women with polycystic ovary syndrome. Clin Endocrinol 1999; 51:231-236.
21. Glueck CJ, Wang P, Fontaine R, et al. Metformin to restore normal menses in oligo-amenorrheic teenage girls with polycystic ovary syndrome (PCOS). J Adolesc Health 2001; 29:160-169.
22. Ibanez L, Valls C, Ferrer A, et al. Sensitization to insulin induces ovulation in nonobese adolescents with anovulatory hyperandrogenism. J Clin Endocrinol Metab 2001; 86:3595-3598.
23. BaysalB,BatukanM,Batukan C. Biochemical and body weight changes with metformin in polycystic ovary syndrome. Clin Exp Obstet Gynecol 2001; 28:212-214.
24. Vrbikova J, Hill M, Starka L, et al. Prediction of the effect of metformin treatment in patients with polycystic ovary syndrome. Gynecol Obstet Invest 2002; 53:100-104.
25. Crave JC, Fimbel S, Lejeune H, et al. Effects of diet and metformin administration on sex hormone-binding globulin, androgens, and insulin in hirsute and obese women. J Clin Endocrinol Metab 1995; 80:2057-2062.
26. Pasquali R, Gambineri A, Biscotti D, et al. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab 2000; 85:2767-2774.
27. Costello MF, Shrestha B, Eden J, et al. Metformin versus oral contraceptive pill in polycystic ovary syndrome: a Cochrane review. Hum Reprod 2007; 22:1200-1209.
28. Palomba S, Oppedisano R, Tolino A, et al. Metformin use in infertile patients with polycystic ovary syndrome: an evidence-based overview. Reprod Biomed Online 2008; 16:327-335.
29. Sackett DL, Rosenberg WM, Gray JA,et al. Evidence basedmedicine: what it is and what it isn't. BMJ 1996; 312:71-72.
30. Lord JM, Flight IH, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 2003; 327:951-953.
31. Kashyap S, Wells GA, Rosenwaks Z. Insulin-sensitizing agents as primary therapy for patients with polycystic ovarian syndrome. Hum Reprod 2004; 19:2474-2483.
32. Moll E, van der Veen F, van Wely M. The role of metformin in polycystic ovary syndrome: a systematic review. Hum Reprod Update 2007; 13:527-537.
33. PalombaS, Orio F Jr, Falbo A, et al. Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90:4068-4074.
34. Legro RS, Barnhart HX, Schlaff WD, et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med 2007; 356:551 -566.
35. Palomba S, Falbo A. Metformin in therapy naive patients with polycystic ovary syndrome. Hum Reprod Update 2008; 14:193.
36. PalombaS, Orio F Jr, Zullo F. What is the best first-step therapeutic approach in treating anovulatory infertility in patients with polycystic ovary syndrome? Questions that are still unanswered. Gynecol Endocrinol 2007; 23:245-247.
37. Moll E, Bossuyt PM, Korevaar JC, et al. Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ 2006; 332:1485-1491.
38. Ng EH, Wat NM, Ho PC. Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene-resistant polycystic ovaries: a randomized, double-blinded placebo-controlled trial. Hum Reprod 2001; 16:1625-1631.
39. Palomba S, Orio F Jr, Nardo LG, et al. Metformin administration versus laparoscopic ovarian diathermy in clomiphene citrate-resistant women with polycystic ovary syndrome: a prospective parallel randomized double-blind placebo-controlled trial. J Clin Endocrinol Metab 2004; 89:4801-4809.
40. Kocak I, Ustun C. Effects of metformin on insulin resistance, androgen concentration, ovulation and pregnancy rates in women with polycystic ovary syndrome following laparoscopic ovarian drilling. J Obstet Gynaecol Res 2006; 32:292-298.
41. SiebertTI, KrugerTF, Steyn DW, et al. Is the addition of metformin efficacious in the treatment of clomiphene citrate-resistant patients with polycystic ovary syndrome? A structured literature review. Fertil Steril 2006; 86:1432-1437.
42. Sohrabvand F, Ansari Sh, Bagheri M. Efficacy of combined metformin-letrozole in comparison with metformin-clomiphene citrate in clomiphene-resistant infertile women with polycystic ovarian disease. Hum Reprod 2006; 21:1432-1435.
43. Khorram O, Helliwell JP, Katz S, et al. Two weeks of metformin improves clomiphene citrate-induced ovulation and metabolic profiles in women with polycystic ovary syndrome. Fertil Steril 2006; 85:1448-1451.
44. Nestler JE, Jakubowicz DJ, Evans WS, et al. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 1998; 338:1 876-1880.
45. Palomba S, Orio F Jr, Falbo A, et al. Metformin administration and laparoscopic ovarian drilling improve ovarian response to clomiphene citrate (CC) in oligo-anovulatory clomiphene citrate-resistant women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2005; 63:631-635.
46. Hwu YM, Lin SY, Huang WY, et al. Ultra-short metformin pretreatment for clomiphene citrate-resistant polycystic ovary syndrome. Int J Gynaecol Obstet 2005; 90:39-43.
47. George SS, George K, Irwin C, et al. Sequential treatment of metformin and clomiphene citrate in clomiphene-resistant women with polycystic ovary syndrome: a randomized, controlled trial. Hum Reprod 2003; 18:299-304.
48. Sahin Y, Yirmibes U, Kelestimur F, et al. The effects of metformin on insulin resistance, clomiphene-induced ovulation and pregnancy rates in women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2004; 113:214-220.
49. Sturrock ND, Lannon B, Fay TN. Metformin does not enhance ovulation induction in clomiphene resistant polycystic ovary syndrome in clinical practice. Br J Clin Pharmacol 2002; 53:469-473.
50. CostelloMF, Chapman M, Conway U. A systematic review and meta-analysis of randomized controlled trials on metformin co-administration during gonadotrophin ovulation induction or IVF in women with polycystic ovary syndrome. Hum Reprod 2006; 21:1387-1399.
51. Gorry A, White DM, Franks S. Infertility in polycystic ovary syndrome: focus on low-dose gonadotropin treatment. Endocrine 2006; 30:27-33.
52. Palomba S, Falbo A, Orio F Jr, et al. A randomized controlled trial evaluating metformin pretreatment and co-administration in nonobese insulin-resistant women with polycystic ovary syndrome treated with controlled ovarian stimulation plus timed intercourse or intrauterine insemination. Hum Reprod 2005; 20:2879-2886.
53. Azziz R, Ehrmann D, Legro RS, et al., PCOS/Troglitazone Study Group. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab 2001; 86:1626-1632.
54. Cataldo NA, Abbasi F, McLaughlin TL, et al. Improvement in insulin sensitivity followedbyovulationandpregnancyinawomanwithpolycysticovarysyndrome who was treated with rosiglitazone. Fertil Steril 2001; 76:1057-1059.
55. Glueck CJ, Moreira A, Goldenberg N, et al. Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin. Hum Reprod 2003; 18:1618-1625.
56. Brettenthaler N, De Geyter C, Huber PR, et al. Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunc-tionin women with polycysticovary syndrome. J Clin Endocrinol Metab 2004; 89:3835-3840.
57. Ortega-González C, Luna S, Hernández L, et al. Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90:1360-1365.
58. Dereli D, Dereli T, Bayraktar F, et al. Endocrine and metabolic effects of rosiglitazone in nonobese women with polycystic ovary disease. Endocr J 2005; 52:299-308.
59. Rautio K, Tapanainen JS, Ruokonen A, et al. Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: a randomized placebo-controlled study. Hum Reprod 2006; 21:1400-1407.
60. Baillargeon JP, Jakubowicz DJ, Iuorno MJ, et al. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertil Steril 2004; 82:893-902.
61. Legro RS, Zaino RJ, Demers LM, et al. The effects of metformin and rosigli-tazone, alone and in combination, on the ovary and endometrium in polycystic ovary syndrome. Am J Obstet Gynecol 2007; 196:402.e1-402.e10.
62. Shobokshi A, Shaarawy M. Correction of insulin resistance and hyperan-drogenism in polycystic ovary syndrome by combined rosiglitazone and clomiphene citrate therapy. J Soc Gynecol Investig 2003; 10:99-104.
63. Ghazeeri G, Kutteh WH, Bryer-Ash M, et al. Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome. Fertil Steril 2003; 79:562-566.
64. Rouzi AA, Ardawi MS. A randomized controlled trial of the efficacy of rosiglitazone and clomiphene citrate versus metformin and clomiphene citrate in women with clomiphene citrate-resistant polycystic ovary syndrome. Fertil Steril 2006; 85:428-435.
65. Coetzee EJ, Jackson WPU. Metformin in management of pregnant insulin-independent diabetics. Diabetologia 1979; 16:241-245.
66. Coetzee EJ, Jackson WPU. Oral hypoglycaemics in the first trimester and fetal outcome. S Afr Med J 1984; 65:635-637.
67. Coetzee EJ, Jackson WP. The management of noninsulin-dependent diabetes during pregnancy. Diabetes Res Clin Pract 1985; 1:281-287.
68. Thatcher SS, Jackson EM. Pregnancy outcome in infertile patients with poly-cystic ovary syndrome who were treated with metformin. Fertil Steril 2006; 85:1002-1009.
69. Glueck CJ, Phillips H, Cameron D, et al. Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. Fertil Steril 2001; 75:46- 52.
70. Glueck CJ, Wang P, Kobayashi S, et al. Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. Fertil Steril 2002; 77:520-525.
71. Jakubowicz DJ, Iuorno MJ, Jakubowicz S, et al. Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J Clin Endocrinol Metab 2002; 87:524-529.
72. Palomba S, Falbo A, Orio F Jr, et al. Metformin hydrochloride and recurrent miscarriage in a woman with polycystic ovary syndrome. Fertil Steril 2006; 85:1511.e3-1511.e5.
73. Palomba S, Orio F Jr, Falbo A, et al. Plasminogen activator inhibitor 1 and miscarriage after metformin treatment and laparoscopic ovarian drilling in patients with polycystic ovary syndrome. Fertil Steril 2005; 84:761-765.
74. Schachter M, Raziel A, Friedler S, et al. Insulin resistance in patients with polycystic ovary syndrome is associated with elevated plasma homocysteine. Hum Reprod 2003; 18:721-727.
75. Diamanti-Kandarakis E, Piperi C, Kalofoutis A, et al. Increased levels of serum advanced glycation end-products in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2005; 62:37-43.
76. Orio F Jr, Palomba S, Cascella T, et al. Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: results of a 6-month study. J Clin Endocrinol Metab 2005; 90:6072-6076.
77. Jakubowicz DJ, Paulina AE, Seppa M, et al. Reduced serum glycodelin and insulin-like growth factor-binding protein-1 in women with polycystic ovary syndrome during first trimester of pregnancy. J Clin Endocrinol Metab 2004; 89:833-839.
78. Schwartz LB, Chiu AS, Courtney M, et al. The embryo versus endometrium controversy revisited as it relates to predicting pregnancy outcome in in-vitro fertilization-embryo transfer cycles. Hum Reprod 1997; 12: 45-50.
79. Jakubowicz DJ, Seppälä M,JakubowiczS,et al. Insulin reduction with metformin increases luteal phase serum glycodelin and insulin-like growth factor-binding protein 1 concentrations and enhances uterine vascularity and blood flow in the polycystic ovary syndrome. J Clin Endocrinol Metab 2001; 86:1126- 1133.
80. Palomba S, Russo T, Falbo A, et al. Clinical use of the perifollicular vascularity assessment in IVF cycles: a pilot study. Hum Reprod 2006; 21:1055- 1061.
81. Van Blerkom J, Antczak M, Schrader R. The developmental potential of the human oocyte is related to the dissolved oxygen content of follicular fluid: association with vascular endothelial growth factor levels and perifollicular blood flow characteristics. Hum Reprod 1997; 12:1047- 1055.
82. Van Blerkom J, Sinclair J, Davis P. Mitochondrial transfer between oocytes: potential applications of mitochondrial donation and the issue of hetero-plasmy. Hum Reprod 1998; 13:2857-2868.
83. Palomba S, Russo T, Orio F Jr, et al. Uterine effects of clomiphene citrate in women with polycystic ovary syndrome: a prospective controlled study. Hum Reprod 2006; 21:2823-2829.
84. Brosens IA. Morphological changes in the utero-placental bed in pregnancy hypertension. Clin Obstet Gynaecol 1977; 4:573-593.
85. Prefumo F, Sebire NJ, Thilaganathan B. Decreased endovascular trophoblast invasion in first trimester pregnancies with high-resistance uterine artery Doppler indices. Hum Reprod 2004; 19:206- 209.
86. Salvesen KA, Vanky E, Carlsen SM. Metformin treatment in pregnant women with polycystic ovary syndrome: is reduced complication rate mediated by changes in the uteroplacental circulation? Ultrasound Obstet Gynecol 2007; 29:433-437.
87. Glueck CJ, Wang P, Goldenberg N, et al. Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. Hum Reprod 2002; 17:2858-2864.
88. Glueck CJ, Goldenberg N, Wang P, et al. Metformin during pregnancy reduces insulin, insulin resistance, insulin secretion, weight, testosterone and development of gestational diabetes: prospective longitudinal assessment of women with polycystic ovary syndrome from preconception throughout pregnancy. Hum Reprod 2004; 19:510-521.
89. Vanky E, Salvesen KA, Hjorth-Hansen H, et al. Beneficial effect of metformin on pregnancy outcome in women with polycystic ovary syndrome is not associated with major changes in C-reactive protein levels or indices of coagulation. Fertil Steril 2006; 85:770-774.
90. Diamant YZ, Rimon E, Evron S. High incidence of preeclamptic toxemia in patients with polycystic ovarian disease. Eur J Obstet Gynecol Reprod Biol 1982; 14:199-204.
91. Kashyap S, Claman P. Polycystic ovary disease and the risk of pregnancy-induced hypertension. J Reprod Med 2000; 45:991-994.
92. Urman B, Sarac E, Dogan L, et al. Pregnancy in infertile PCOD patients. Complications and outcome. J Reprod Med 1997; 42:501-505.
93. Bjercke S, Dale PO, Tanbo T, et al. Impact of insulin resistance on pregnancy complications and outcome in women with polycystic ovary syndrome. Gynecol Obstet Invest 2002; 54:94-98.
94. Wolf M, Sandler L, Mun̄oz K, et al. First trimester insulin resistance and subsequent preeclampsia: a prospective study. J Clin Endocrinol Metab 2002; 87:1563-1568.
95. Glueck CJ, Salehi M, Sieve L, et al. Growth, motor, and social development in breast- and formula-fed infants of metformin-treated women with polycystic ovary syndrome. J Pediatr 2006; 148:628-632.
96. Hellmuth E, Damm P, Moølsted-Pedersen L. Oral hypoglycaemic agents in 118 diabetic pregnancies. Diabet Med 2000; 17:507-511.
97. Glueck CJ, Goldenberg N, Pranikoff J, et al. Height, weight, and motor-social development during the first 18 months of life in 126 infants born to 109 mothers with polycystic ovary syndrome who conceivedonand continued metformin through pregnancy. Hum Reprod 2004; 19:1323-1330.
98. Gilbert C, Valois M, Koren G. Pregnancy outcome after first-trimester exposure to metformin: a meta-analysis. Fertil Steril 2006; 86:658-663.
99. Avandia (rosiglitazone maleate) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline, 2005.
100. Goldenberg N, Glueck C. Medical therapy in women with polycystic ovarian syndrome before and during pregnancy and lactation. Minerva Ginecol 2008; 60:63-75.
101. Chan LY, Lau TK. Effectofrosiglitazoneonembryonicgrowth and morphology: a study using a whole rat embryo culture model. Fertil Steril 2006; 86:490- 492.
102. Yaris F, Yaris E, Kadioglu M, et al. Normal pregnancy outcome following inadvertent exposure to rosiglitazone, gliclazide, and atorvastatin in a diabetic and hypertensive woman. Reprod Toxicol 2004; 18:619-621.
103. Kalyoncu NI, Yaris F, Ulku C, et al. A case of rosiglitazone exposure in the second trimester of pregnancy. Reprod Toxicol 2005; 19:563-564.